Pfizer licenses exclusive rights to Repligen's SMA program; terminated
- Includes Royalty or Profit Split Information
- R+D and Marketing-Licensing
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.